Patients The ins and outs of HEOR – A lever for global health Web editor Nicole Raleigh speaks with Rob Abbott, CEO and executive director of ISPOR, about the ins and outs and trends of HEOR.
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
